We are live on ! Find out more
WP

Woodline Partners Portfolio holdings

AUM $26.4B
1-Year Est. Return 44.85%
This Fund
S&P 500
This Quarter Est. Return
+4.94%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
AUM
$6.98B
AUM Growth
+$857M
Cap. Flow
+$784M
Cap. Flow %
11.24%
Top 10 Hldgs %
16.48%
Holding
878
New
205
Increased
124
Reduced
98
Closed
184

Top Sells

Rank Stock Value
1
TER icon
Teradyne
TER
+$132M
2
QCOM icon
Qualcomm
QCOM
+$77.3M
3
ABT icon
Abbott
ABT
+$69.2M
4
BKNG icon
Booking.com
BKNG
+$67.7M
5
KLAC icon
KLA
KLAC
+$63.2M

Sector Composition

Rank Sector Weight
1 Healthcare 41.18%
2 Technology 29.45%
3 Communication Services 6.73%
4 Industrials 6.43%
5 Financials 4.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
OPCH icon
251
Option Care Health
OPCH
$3.51B
$6.63M 0.09%
232,958
+165,188
+244% +$4.34M
SEEL
252
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$6.6M 0.09%
1,054
-86
-8% -$660K
VERV
253
DELISTED
Verve Therapeutics
VERV
$6.49M 0.09%
176,027
-26,473
-13% -$1.11M
ATAI icon
254
AtaiBeckley Inc
ATAI
$2.66B
$6.39M 0.09%
838,026
+88,007
+12% +$1.07M
ERAS icon
255
Erasca
ERAS
$6.51B
$6.39M 0.09%
410,070
-23
-0% -$394
TBPH icon
256
Theravance Biopharma
TBPH
$876M
$6.36M 0.09%
575,113
-1,404,017
-71% -$12.2M
DICE
257
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$6.33M 0.09%
250,049
-9
-0% -$264
RDNT icon
258
RadNet
RDNT
$5.23B
$6.29M 0.09%
209,062
+45,151
+28% +$1.33M
EWTX icon
259
Edgewise Therapeutics
EWTX
$4.84B
$6.16M 0.09%
402,849
+41,028
+11% +$738K
DYN icon
260
Dyne Therapeutics
DYN
$4.92B
$6.12M 0.09%
514,601
+298,400
+138% +$4.19M
PRAX icon
261
Praxis Precision Medicines
PRAX
$8.86B
$6.08M 0.09%
20,583
RBAC
262
DELISTED
RedBall Acquisition Corp.
RBAC
$5.95M 0.09%
+600,000
New +$6M
DSAC
263
DELISTED
Duddell Street Acquisition Corp. Class A Ordinary Shares
DSAC
$5.95M 0.09%
+600,000
New +$5.92M
PRGO icon
264
Perrigo
PRGO
$1.84B
$5.9M 0.08%
151,639
S icon
265
SentinelOne
S
$7.26B
$5.89M 0.08%
116,668
COHR
266
DELISTED
Coherent Inc
COHR
$5.87M 0.08%
22,020
+5,064
+30% +$1.31M
HCIC
267
DELISTED
Hennessy Capital Investment Corp. V Class A Common Stock
HCIC
$5.84M 0.08%
600,002
AGGR
268
DELISTED
Agile Growth Corp
AGGR
$5.82M 0.08%
599,999
ALT icon
269
Altimmune
ALT
$591M
$5.68M 0.08%
620,678
+271,855
+78% +$2.89M
SNPO
270
DELISTED
Snap One Holdings Corp. Common Stock
SNPO
$5.53M 0.08%
262,142
JANX icon
271
Janux Therapeutics
JANX
$974M
$5.49M 0.08%
278,275
-21,756
-7% -$456K
THC icon
272
Tenet Healthcare
THC
$21.1B
$5.47M 0.08%
66,995
-41,633
-38% -$3.04M
TNGX icon
273
Tango Therapeutics
TNGX
$4.73B
$5.47M 0.08%
500,018
-22
-0% -$265
CCXI
274
DELISTED
ChemoCentryx, Inc.
CCXI
$5.4M 0.08%
+148,295
New +$5.21M
ONEM
275
DELISTED
1Life Healthcare
ONEM
$5.39M 0.08%
307,070
+250,030
+438% +$4.85M

Similar funds

Woodline Partners's Q4 2021 Portfolio in Review

As of Q4 2021, Woodline Partners held 878 positions worth $6.98B, up 14% from $6.12B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

Woodline Partners deployed $784M of net new capital in Q4 2021, opening 205 new positions and adding to 124 existing holdings. Its largest new stake was Qorvo: 963,210 shares worth $151M.

By sector, the portfolio is most concentrated in Healthcare at 41% of assets, down from 46% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was KLA, an estimated $63.2M trimmed.

  • Woodline Partners's largest Q4 2021 buy was Qorvo: 963,210 shares worth $151M.
  • Woodline Partners added most to ASML in Q4 2021, an estimated $117M increase.
  • Woodline Partners's biggest Q4 2021 reduction was KLA, cutting an estimated $63.2M.
  • Woodline Partners fully exited Teradyne in Q4 2021, selling an estimated $132M.
  • Woodline Partners's ten largest holdings make up 16% of its $6.98B portfolio in Q4 2021.
  • Woodline Partners opened 205 new positions and closed 184 in Q4 2021.
  • Woodline Partners's portfolio value rose 14% quarter-over-quarter to $6.98B.

Based on Woodline Partners's 13F filing for Q4 2021, filed 14 Feb 2022.